Last reviewed · How we verify
Phase 1b Study of CAR2Anti-CEA CAR-T Cell Hepatic Infusions for Pancreatic Carcinoma Patients With CEA+ Liver Metastases (AntiCEA_CART)
This study is an open-label, single arm phase 1b safety study of CAR2 Anti-CEA CAR-T cell hepatic arterial infusions for pancreatic carcinoma patients with carcinoembryonic antigen positive (CEA+) liver metastases resistant to standard therapy who meet all other eligibility criteria.
Details
| Lead sponsor | Sorrento Therapeutics, Inc. |
|---|---|
| Phase | PHASE1 |
| Status | TERMINATED |
| Enrolment | 2 |
| Start date | Mon Jul 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Fri May 21 2021 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Metastatic Pancreatic Carcinoma
Interventions
- CAR2 Anti-CEA CAR-T cells
Countries
United States